Cysteamine is an organosulfur compound with the formula HSCH2CH2NH2. A white, water-soluble solid, it contains both an amine and a thiol functional groups. It is often used as salts of the ammonium derivative [HSCH2CH2NH3]+[12] including the hydrochloride, phosphocysteamine, and the bitartrate.[13]The intermediate pantetheine is broken down into cysteamine and pantothenic acid.[13]
It is biosynthesized in mammals, including humans, by the degradation of coenzyme A. It is the biosynthetic precursor to the neurotransmitter hypotaurine.[14][13]
When applied topically it can lighten skin that's been darkened as a result of post-inflammatory hyperpigmentation, sun exposure and Melasma.[18][19][20][21] Tentative evidence suggests that it may be a more effective depigmentation agent than hydroquinone, retinoids and topical corticosteroids in individuals with chronic skin discoloration.[22][23][24] Topical application of cysteamine cream has also demonstrated similar efficacy to intradermaltranexamic acid injections for the treatment of Melasma but with much fewer adverse effects.[25]
Adverse effects
Topical use
The most important adverse effect related to topical use might be skin irritation.[medical citation needed] However it's significantly better tolerated than alternative skin lightening treatments with similar efficacy.[24][25]
Oral use
The label for oral formulations of cysteamine carry warnings about symptoms similar to Ehlers-Danlos syndrome, severe skin rashes, ulcers or bleeding in the stomach and intestines, central nervous symptoms including seizures, lethargy, somnolence, depression, and encephalopathy, low white blood cell levels, elevated alkaline phosphatase, and idiopathic intracranial hypertension that can cause headache, tinnitus, dizziness, nausea, double or blurry vision, loss of vision, and pain behind the eye or pain with eye movement.[8]
Additional adverse effects of oral cysteamine include bad breath, skin odor, vomiting, nausea, stomach pain, diarrhea, and loss of appetite.[8]
The drug is in pregnancy category C; the risks of cysteamine to a fetus are not known but it harms babies in animal models at doses less than those given to people.[6][7]
For eye drops, the most common adverse effects are sensitivity to light, redness, and eye pain, headache, and visual field defects.[7]
Interactions
There are no drug interactions for normal capsules or eye drops,[6][7] but the extended release capsules should not be taken with drugs that affect stomach acid like proton pump inhibitors or with alcohol, as they can cause the drug to be released too quickly.[8] It doesn't inhibit any cytochrome P450 enzymes.[8]
Pharmacology
People with cystinosis lack a functioning transporter (cystinosin) which transports cystine from the lysosome to the cytosol. This ultimately leads to buildup of cystine in lysosomes, where it crystallizes and damages cells.[16] Cysteamine enters lysosomes and converts cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome.[8]
Cysteamine also promotes the transport of L-cysteine into cells.[13]
In 2013, the regular capsule of cysteamine cost about $8,000 per year; the extended release form that was introduced that year was priced at $250,000 per year.[28]
History
The therapeutic effect of cysteamine on cystinosis was reported in the 1950s. Cysteamine was approved as a drug for cystinosis in the US in 1994.[8] An extended release form was approved in 2013.[28]
It was studied in in vitro and animal models for radiation protection in the 1950s, and in similar models from the 1970s onwards for sickle cell anemia, effects on growth, its ability to modulate the immune system, and as a possible inhibitor of HIV.[13]
^Reid EE (1958). Organic Chemistry of Bivalent Sulfur. Vol. 1. New York: Chemical Publishing Company, Inc. pp. 398–399.
^ abcdefghiBesouw M, Masereeuw R, van den Heuvel L, Levtchenko E (August 2013). "Cysteamine: an old drug with new potential". Drug Discovery Today. 18 (15–16): 785–792. doi:10.1016/j.drudis.2013.02.003. PMID23416144.
^Gahl WA, Thoene JG, Schneider JA (July 2002). "Cystinosis". The New England Journal of Medicine. 347 (2): 111–121. doi:10.1056/NEJMra020552. PMID12110740.
^ abcNesterova G, Gahl WA (6 October 2016). "Cystinosis". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews. Seattle WA: University of Washington. PMID20301574. Archived from the original on 5 April 2011. Retrieved 11 January 2017.
^Mansouri P, Farshi S, Hashemi Z, Kasraee B (July 2015). "Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial". The British Journal of Dermatology. 173 (1): 209–217. doi:10.1111/bjd.13424. PMID25251767. S2CID21618233.
^Mathe N, Balogun M, Yoo J (January 2021). "A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids)". Journal of Cosmetic Dermatology. 20 (1): 204–206. doi:10.1111/jocd.13755. PMID32997864. S2CID222163129.
^Kasraee B, Mansouri P, Farshi S (February 2019). "Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula". Journal of Cosmetic Dermatology. 18 (1): 293–295. doi:10.1111/jocd.12837. PMID30537063. S2CID54481706.
^ abKarrabi M, David J, Sahebkar M (January 2021). "Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study". Skin Research and Technology. 27 (1): 24–31. doi:10.1111/srt.12901. PMID32585079. S2CID220078010.
